- The report reviews Midkine ( Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK ) targeted therapeutics under development by companies and universities / research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes , product description , descriptive MoA , R & D brief , licensing and collaboration details & other developmental activities - The report reviews key players involved in Midkine ( Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK ) targeted therapeutics and enlists all their major and minor projects - The report assesses Midkine ( Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK ) targeted therapeutics based on mechanism of action ( MoA ), route of administration ( RoA ) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Midkine ( Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK ) targeted therapeutics
Reasons To Buy - Gain strategically significant competitor information , analysis , and insights to formulate effective R & D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Midkine ( Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK ) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it ' s most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Midkine ( Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK ) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Buy a Sample Copy of This Report @ http :// www . radiantinsights . com / research / midkine-amphiregulinassociated-protein-or-midgestation-and-kidney-protein-or-neurite-outgrowth-promoting-factor-2-or-mdkpipeline-review-h2-2016 / request-sample
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Midkine ( Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK ) Overview 6 Midkine ( MDK ) or neurite growth-promoting factor 2 is a protein encoded by the MDK gene . It binds to anaplastic lymphoma kinase which induces ALK activation and subsequent phosphorylation of the insulin receptor substrate , activation of mitogen-activated protein kinase and PI3-kinase and the induction of cell proliferation . It is involved in neointima formation after arterial injury and early fetal adrenal gland development . 6 Therapeutics Development 7 Midkine ( Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK ) - Products under Development by Stage of Development 7 Midkine ( Amphiregulin Associated Protein or Midgestation And Kidney Protein or Neurite Outgrowth Promoting Factor 2 or MDK ) - Products under Development by Therapy Area 8